OKYO Pharma (NASDAQ:OKYO) Price Target Lowered to $5.00 at HC Wainwright

OKYO Pharma (NASDAQ:OKYO) had its price objective dropped by equities research analysts at HC Wainwright from $7.00 to $5.00 in a report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 195.86% from the stock’s current price.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of OKYO Pharma in a research report on Tuesday, April 21st. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $5.67.

OKYO Pharma Stock Performance

Shares of OKYO Pharma stock opened at $1.69 on Monday. The firm’s 50 day simple moving average is $1.61 and its two-hundred day simple moving average is $1.78. OKYO Pharma has a 12-month low of $1.42 and a 12-month high of $3.35.

Institutional Trading of OKYO Pharma

Institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC increased its stake in shares of OKYO Pharma by 235.0% in the fourth quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after acquiring an additional 96,800 shares during the period. XTX Topco Ltd acquired a new stake in OKYO Pharma during the 4th quarter worth about $36,000. Finally, Citadel Advisors LLC purchased a new position in shares of OKYO Pharma during the 3rd quarter valued at about $31,000. 2.97% of the stock is currently owned by institutional investors and hedge funds.

About OKYO Pharma

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.